I’m excited to share a deeper look into my professional journey in oncology research, clinical development, and regulatory science. Over the past 30+ years, I’ve had the opportunity to work across global biopharma organizations, advisory boards, and academic institutions, all focused on advancing patient-centered innovation. Here is my biography.

I’m grateful for the opportunities I’ve had throughout my career to work alongside incredible teams, lead transformational initiatives, and help strengthen healthcare operations across diverse organizations. As I continue to grow and explore new avenues for impact—especially in governance and advisory roles—I’m pleased to share a more complete picture of my professional journey and the values that shape my leadership. Here is my biography.

Artificial intelligence is reshaping healthcare, but its real impact comes less from flashy promises and more from disciplined, outcome-driven execution. Rather than adopting AI for its own sake, successful organizations start with a clearly defined operational or clinical problem—like reducing administrative burden, improving access to timely information, or accelerating decision-making—and then design solutions with governance, privacy, and accountability built in from the start. The most effective AI tools integrate seamlessly into existing workflows, augmenting clinicians and operational teams instead of disrupting how they work. By moving quickly through focused pilots, proving value early, and measuring success through meaningful outcomes (cost, efficiency, patient experience, and staff satisfaction), healthcare leaders can treat AI as a practical enabler of better care—not the goal itself.

I’m excited to share a more complete view of my professional journey and leadership philosophy, shaped by years of experience in healthcare analytics, value-based care, and executive leadership. I’m passionate about using data, strategy, and collaboration to create meaningful impact and support organizations as they grow and evolve. Here is my biography.

I’m proud to share an updated version of my professional biography, reflecting the work, values, and experiences that have shaped my career in psychiatry, neuroscience, trauma studies, and mental health innovation. The journey has been deeply meaningful, and I remain committed to advancing care through science, compassion, and creative thinking.

I am grateful for the opportunities I’ve had over the past two decades to work alongside hospitals, physician groups, technology companies, and healthcare leaders to strengthen revenue cycle performance, improve operations, and support better outcomes for patients and providers. My journey has taken me from patient access and hospital operations to national leadership roles, consulting, and healthcare technology innovation, and I remain passionate about leveraging that experience to help organizations grow and adapt. Here is my biography.

I am excited to share my professional executive biography, which highlights my journey across medical devices, commercialization, and clinical leadership. With over fourteen years of experience in MedTech and global healthcare, I remain committed to advancing patient outcomes and driving innovation at the intersection of clinical expertise and business strategy.

I’m excited to share my professional biography, which reflects my journey as a neurologist, healthcare executive, and innovator passionate about integrating technology into patient care. From leading clinical teams to advising global medtech companies, and from building a healthcare startup to advancing AI in medicine, my career has been dedicated to bridging science, business, and innovation.

Deb Kelly is a pioneering leader in biomedical research, known for her expertise in molecular biophysics, computational modeling, and high-resolution imaging to advance translational medicine. As Executive Director of Structural Oncology LLC and a professor at Penn State University, she has led groundbreaking research in cancer and viral health threats, integrating artificial intelligence and bioinformatics to drive drug discovery and clinical decision-making. With over 15 years of experience managing multidisciplinary teams, securing millions in research funding, and mentoring early-career professionals, Kelly’s work has had a lasting impact on biomedical science. Her strategic leadership, innovative research, and commitment to mentorship continue to shape the future of medical advancements and therapeutic development.

The healthcare investment landscape is undergoing a revolutionary transformation, addressing the binary risk and inefficiency that have long plagued therapeutic R&D. Traditional drug development processes are slow, costly, and fraught with failure, but advances in AI are now enabling faster, more accurate drug discovery and validation. Leveraging this potential, a novel funding model has emerged, combining insurance underwriting by Lloyd’s of London and non-dilutive lending, supported by AI-driven validation technology from GATC Health. This approach reduces risk for all stakeholders, accelerates funding timelines, and maximizes the chances of success for biotech startups. With nearly 100 startups already in the pipeline, this innovative funding vehicle promises to expedite therapeutic breakthroughs, benefiting investors, companies, and most importantly, patients in need.